Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Where Regeneron Pharmaceuticals Stands With Analysts
02:01pm, Thursday, 09'th Mar 2023 Benzinga
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
6
4
2 Biotech Stocks You Can Buy and Hold for the Next Decade
01:30pm, Thursday, 09'th Mar 2023 The Motley Fool
Regeneron and Sarepta Therapeutics have been on fire so far this year.
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
02:10pm, Wednesday, 08'th Mar 2023 Zacks Investment Research
Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
06:00am, Tuesday, 07'th Mar 2023 GlobeNewswire Inc.
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihista
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
12:05pm, Monday, 06'th Mar 2023 The Motley Fool
The French drug company got the nod for a hemophilia treatment.
Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback
05:24pm, Wednesday, 01'st Mar 2023 Zacks Investment Research
Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
01:00am, Wednesday, 01'st Mar 2023 GlobeNewswire Inc.
Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial
Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak
06:49pm, Tuesday, 28'th Feb 2023 Zacks Investment Research
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
04:36pm, Friday, 24'th Feb 2023 Zacks Investment Research
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
01:58pm, Friday, 24'th Feb 2023 Zacks Investment Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly ap
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
12:45pm, Friday, 24'th Feb 2023 GlobeNewswire Inc.
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone Recommendation based on a Phase 3 trial demonstrating supe
3 More Mid-Cap Biotechs the Street Sees Doubling
05:30am, Thursday, 23'rd Feb 2023 Investing.com
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review
04:36pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.
Three-Stock Lunch: Regeneron, General Mills and DocuSign
03:45pm, Tuesday, 21'st Feb 2023
Eva Ados, chief investment strategist at ERShares, joins ‘Power Lunch' to discuss Regeneron, General Mills and DocuSign.
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review
12:48pm, Tuesday, 21'st Feb 2023
Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.
